ClinicalTrials.gg
Active, not recruitingNCT07948564NCCL-BondUpdated Nov 19, 2026

Effect of Desensitizing Agents on Bond Strength and Clinical Performance of Composite Restorations

An interventional study of Nano-hydroxyapatite paste and CPP-ACP paste in Non-carious Cervical Lesions and Dentin Hypersensitivity, sponsored by Faculty of Dental Medicine for Girls. Active, not recruiting at 1 site in Egypt. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Faculty of Dental Medicine for Girls · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Sep 2025, registered Nov 2026).
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 36 studies in Dentin Sensitivity with a site in Egypt — 8 open to participants now, 11 under way, 1 of them phase 3. Dentin Sensitivity · Egypt.

Enrollment
23rd of 35
30 · median 46
Started
2025
with 6 others
No phase
27 of 36
7 open now
Primary completion
2026-12
later than 7 of 10 live
Registered
36th of 36
by date
Lead sponsor
3 of 36
Faculty of Dental Medicine for Girls

Among the 36 studies in Dentin Sensitivity with a site in Egypt, this one is the 23rd largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2025, is one of 27 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 36th registered.

Dentin Sensitivity

292 studies on the registry are indexed under Dentin Sensitivity; 49 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

8 of the 36 studies in Dentin Sensitivity with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 20 Dentin Sensitivity studies recruiting now, 6 (30%) set no upper age limit and 13 (65%) stop at 75 or younger; 2 take children under 18; 12 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Dentin Sensitivity with a site in Egypt, or all of them as a file.
02

Study summary

This study evaluates the effect of different desensitizing agents (Nano-hydroxyapatite and Casein Phosphopeptide-Amorphous Calcium Phosphate pastes) with different bonding techniques (etch-and-rinse or self-etch) on the tensile bond strength of resin composite to dentin (in vitro) and on the clinical performance (retention and marginal integrity evaluated by FDI criteria) of resin composite restorations in non-carious cervical lesions (NCCLs) over a 12-month period (in vivo).

Read the detailed description

Non-carious cervical lesions (NCCLs) present restoration retention challenges due to non-retentive shapes and continuous flexure forces. The primary research objective includes an in vitro laboratory study using 54 extracted human posterior teeth to evaluate tensile bond strength across three pretreatment desensitizing material groups (no treatment control, nano-hydroxyapatite paste, and CPP-ACP paste) and two etching modes (etch-and-rinse vs self-etch). Additionally, an in vivo single-blind randomized clinical trial evaluates 30 non-carious cervical lesions and dentin hypersensitivity. Restoration clinical performance regarding retention and marginal integrity will be clinically assessed at 6-month and 12-month intervals using FDI evaluation criteria.

03

Conditions studied

  • Non-carious Cervical Lesions
  • Dentin Hypersensitivity

Browse trials for

Keywords

  • Desensitizing agents
  • Nano-hydroxyapatite
  • CPP-ACP
  • Etch and rinse
  • Self-etch
  • Tensile bond strength
  • Resin composite
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 20 and 50 years.
  • Cooperative patients with good oral hygiene.
  • Presence of at least one non-carious cervical lesion (NCCL) with dentin .
  • Teeth with positive response to vitality testing.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe systemic diseases or psychological disorders.
  • Pregnant or lactating women.
  • Teeth with deep caries, pulp exposure, or periapical pathology.
  • Chronic periodontitis or poor periodontal condition.
  • Bruxism or severe malocclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Control Group (A0)

    No desensitizing pretreatment applied before bonding procedure.

    Other: Resin Composite Restoration

  • Experimental
    Nano-hydroxyapatite Group (A1)

    Pretreatment with Nano-hydroxyapatite paste before bonding.

    Drug: Nano-hydroxyapatite paste · Other: Resin Composite Restoration

  • Experimental
    CPP-ACP Group (A2)

    Pretreatment with Casein Phosphopeptide-Amorphous Calcium Phosphate paste before bonding.

    Drug: CPP-ACP paste · Other: Resin Composite Restoration

Interventions

  • DrugNano-hydroxyapatite paste

    Applied on open dentinal tubules using a disposable microbrush and polished using a rotary cup before resin composite bonding.

  • DrugCPP-ACP paste

    Casein Phosphopeptide-Amorphous Calcium Phosphate paste applied to dentin prior to adhesive placement.

  • OtherResin Composite Restoration

    Restorative procedure using universal adhesive in etch-and-rinse or self-etch mode followed by resin composite placement.

06

What researchers measure

Primary outcomes

  1. Assessment of restoration retention/fracture

    Retention, scored together with fracture as retention/fracture, is the standard primary outcome in NCCL evaluated with the FDI criteria

    Time frame: From baseline up to 1 year after the restoration day.

Secondary outcomes

  1. Marginal adaptation or marginal integrity.

    Small defects are common and often not clinically decisive, so it sits alongside marginal discoloration, surface texture, postoperative sensitivity, secondary caries and color match evaluated with the FDI criteria.

    Time frame: From baseline up to 1 year after the restoration day.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 112 non-industry interventional studies with no phase under Dentin Sensitivity, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 12. This study's planned 15 months is above that.

Counting every sponsor, half of 146 studies reached it within 6 months; a quarter within 3 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 19, 2026
StartActual
Sep 15, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Jan 15, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948564
Lead sponsor
Faculty of Dental Medicine for Girls
Responsible party
Alaa mousa mohamed (Restorative doctor, Faculty of Dental Medicine for Girls) — Principal investigator
First posted
Nov 19, 2026
Start date
Sep 15, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Jan 15, 2027 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion